Delcath Systems Inc DCTH
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2000-10-19 |
| Shares Out. | 34,520,000 |
| Website | delcath.com/ ↗ |
| Phone | 15187438892 |
| Employees | 156 |
| Revenue | $25.0M |
| Gross Profit | $21.3M |
| Net Income | -$1.1M |
| Free Cash Flow | $19.2M |
| Total Assets | $124.8M |
| Total Liabilities | $12.1M |
| Equity | $112.7M |
About Delcath Systems Inc
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Delcath Systems Inc is a publicly traded company under the ticker symbol DCTH on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)